Skip to main content

Advertisement

SpringerLink
Log in

Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease associated with psoriasis, is a complex disease in terms of its clinical presentation, etiology, and pathogenesis. Musculoskeletal presentations include peripheral arthritis, spondylitis, enthesitis, and dactylitis. To learn about the course of and prognosis for such a complex disease, it is important to observe patients longitudinally so that all aspects of the disease are recognized. Several registries have been developed to evaluate the course of and prognosis for patients with PsA. Based on such registries, it has been shown that PsA is more severe than previously thought, and that progression of joint damage is related to joint inflammation. Such registries also have been used to determine genetic factors in PsA and to identify biomarkers for both susceptibility and expression of the disease. Drug registries also have been developed to document response to new therapies as well as the long-term adverse effects resulting from such therapies. It is hoped that an international effort currently on the way will further enhance the contribution of PsA patient registries to address the etiology, pathogenesis, and outcome of this complex disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Gladman DD, Ritchlin C, Helliwell PS. Psoriatic arthritis clinical registries and genomics. Ann Rheum Dis. 2005;64((Suppl II) ii):103–5.

    Google Scholar 

  2. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.

    Article  PubMed  CAS  Google Scholar 

  3. Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32:181–201.

    Article  PubMed  CAS  Google Scholar 

  4. Lambert JR, Wright V. Psoriatic spondylitis: a clinical and radiological description of the spine in psoriatic arthritis. Q J Med. 1977;46:411–25.

    PubMed  CAS  Google Scholar 

  5. • Gladman DD, Chandran V. Observational cohorts studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatol Online 2010;60:25–31. This paper describes the University of Toronto PsA program and the lessons learned from its registry.

    Google Scholar 

  6. • Nair RP, Duffin KC, Helms C, et al. The Collaborative Association Study of Psoriasis. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199–204. This study included patients from several psoriasis registries and identified several novel genes in the susceptibility to psoriasis and PsA.

    Article  PubMed  CAS  Google Scholar 

  7. Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33:834–9.

    Article  PubMed  CAS  Google Scholar 

  8. Korendowych E, Dixey J, Cox B, et al. The Influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol. 2003;30:96–101.

    PubMed  CAS  Google Scholar 

  9. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778–83.

    Article  CAS  Google Scholar 

  10. Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis—a single-center study from the UK. J Rheumatol. 2010;37:2141214-4.

    Article  Google Scholar 

  11. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis. Results from a single centre. I. Risk and causes of death. Arthritis Rheum. 1997;40:1868–72.

    Article  PubMed  CAS  Google Scholar 

  12. Ali Y, Tom BDM, Schentag CT, et al. Improved survival in psoriatic arthritis (PsA) with calendar time. Arthritis Rheum. 2007;56:2708–14.

    Article  PubMed  Google Scholar 

  13. Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol. 2000;27:1247–50.

    PubMed  CAS  Google Scholar 

  14. Thumboo J, Uramoto K, Shbeeb MI, et al. Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol. 2002;29:757–62.

    PubMed  Google Scholar 

  15. Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36:361–7.

    Article  PubMed  Google Scholar 

  16. Svensson B, Holmstrom G, Lindqvist U. Development and early experiences of a Swedish psoriatic arthritis register. Scand J Rheumatol. 2002;31:221–5.

    Article  PubMed  Google Scholar 

  17. • Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register—2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008;35:668–73. The Swedish early PsA registry includes patients with early PsA who are observed prospectively.

    PubMed  Google Scholar 

  18. Gladman DD, Ng Tung Hing E, Schentag CT, Cook R. Remission in psoriatic arthritis. J Rheumatol. 2001;28:1045–8.

    PubMed  CAS  Google Scholar 

  19. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460–8.

    Article  CAS  Google Scholar 

  20. • Reddy SM, Anandarajah AP, Fisher MC, et al. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. J Rheumatol 2010;37:2566–72. This is a cross-sectional study from a US-based registry. It includes a large number of patients with RA and PsA observed over time. However, the information collected is limited.

    Article  PubMed  Google Scholar 

  21. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis—clinical and laboratory analysis of 220 patients. Quart J Med. 1987;62:127–41.

    PubMed  CAS  Google Scholar 

  22. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809–12.

    PubMed  CAS  Google Scholar 

  23. Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Investig Med. 1995;18:139–43.

    CAS  Google Scholar 

  24. Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol. 1995;22:241–5.

    PubMed  CAS  Google Scholar 

  25. Rahman P, Gladman DD, Zhou Y, Cook RJ. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. 1998;25:1957–61.

    PubMed  CAS  Google Scholar 

  26. Lee JCT, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol. 2001;7:160–5.

    Article  PubMed  CAS  Google Scholar 

  27. Eder L, Chandran V, Shen H, et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology (Oxford). 2010;49:1361–6.

    Article  CAS  Google Scholar 

  28. • Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 2010;49:1367–73. This is the first study to systematically assess the response to intra-articular injections among patients with PsA. Almost half of the patients responded. The presence of damage was detrimental to response. Migration inhibitory factor polymorphisms did not predict response but were associated with recurrence.

    Article  Google Scholar 

  29. • Eder L, Chandran V, Shen H, et al. The incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken) online 15/11/2010. This study demonstrated that the incidence of PsA among patients with psoriasis may be higher than what current figures indicate. This was a prospective cohort of patients with psoriasis observed according to the same standard protocol used in the PsA clinic.

  30. Eder L, Loo T, Chandran V, et al. Environmental risk factors for psoriatic arthritis among patients with psoriasis: a case-control study. Arthritis Rheum. 2010;62 Suppl 10:S809.

    Google Scholar 

  31. Eder L, Chandran V, Pellett F, et al. The association of IL-13 polymorphism with psoriatic arthritis among psoriasis patients. Arthritis Rheum. 2010;62 Suppl 10:S830.

    Google Scholar 

  32. Eder L, Pellett F, Chandran V, et al. HLA-Cw*06 allele increases the duration of time between the onset of psoriasis and psoriatic arthritis. Arthritis Rheum. 2010;62 Suppl 10:S220.

    Google Scholar 

  33. • Glintborg B, Ostergaard M, Dreyer L, et al. Treatment response, drug survival and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the Danish nationwide DANBIO registry. Arthritis Rheum online 27/10/2010. PMID: 20981816. The use of biologics registries to determine drug survival and toxicity was demonstrated by this study from the Danish registry.

  34. Carmona L, Descalzo MA, Ruiz-Montesinos D, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology. 2011;50:85–92.

    Article  PubMed  CAS  Google Scholar 

  35. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.

    Article  PubMed  Google Scholar 

  36. Simard JF, Arkema EV, Sundstrom A, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford). 2011;50:204–13.

    Article  Google Scholar 

  37. Aletaha D. Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. Arthritis Res Ther. 2009;11:112.

    Article  PubMed  Google Scholar 

  38. Brockbank J, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis (PsA): a marker for disease severity? Ann Rheum Dis. 2005;62:188–90.

    Article  Google Scholar 

  39. Queiro R, Torre JC, Belzunegui J, et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum. 2002;31:264–70.

    Article  PubMed  Google Scholar 

  40. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis. Results from a single centre. Ann Rheum Dis. 2007;66:370–6.

    Article  PubMed  Google Scholar 

  41. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis (PsA). Ann Rheum Dis. 2009;68:1131–5.

    Article  PubMed  CAS  Google Scholar 

  42. Rohekar S, Tom BD, Hassa A, et al. Malignancy in psoriatic arthritis. Arthritis Rheum. 2008;58:82–7.

    Article  PubMed  Google Scholar 

  43. • Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010;49:1399–1405. The study demonstrated that there are biomarkers for susceptibility to psoriatic disease, some of which actually distinguish between patients with psoriasis alone and those with PsA.

    Article  CAS  Google Scholar 

  44. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111:821–31.

    PubMed  CAS  Google Scholar 

  45. Chiu YG, Shanmugarajah S, Oanpento B, et al. DC-STAMP (dendritic cell specific transmembrane protein), a potential biomarker to predict the risk of psoriasis patients in developing psoriatic arthritis. Arthritis Rheum. 2101;62 Suppl 10:S217.

    Google Scholar 

  46. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:J314.

    Article  PubMed  CAS  Google Scholar 

  47. Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study reveals association of psoriasis with TRAF3IP2. Nat Genet. 2010;42:991–5.

    Article  PubMed  CAS  Google Scholar 

  48. • Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010;42:1000–4. There are now two large genome-wide association studies that identified patients with PsA. A meta-analysis of those studies identified three new psoriasis and PsA susceptibility loci.

    Article  PubMed  CAS  Google Scholar 

  49. Askling J. Malignancy and rheumatoid arthritis. Curr Rheumatol Rep. 2007;9:421–6.

    Article  PubMed  CAS  Google Scholar 

  50. Toloza SMA, Valle-Oñate R, Espinoza LR. Psoriatic arthritis in South and Central America. Curr Rheum Rep 2011 (in press)

Download references

Acknowledgments

Dr. Chandran has been supported by a Canadian Institutes of Health Research/Clinical Research Initiative Fellowship, the Krembil Foundation, and the CIHR-NET grant on psoriasis and psoriatic arthritis.

Disclosure

Dr. Gladman has served as a consultant for Amgen, Centocor Ortho Biotech, Bristol-Myers Squibb, Merck & Co., Pfizer, and UCB.

Dr. Chandran has served as a consultant for Amgen and Pfizer; has received royalties from Oxford University Press; and has received payment for development of educational presentations, including service on speakers’ bureaus, from Wyeth/Pfizer, Abbott Laboratories, Schering-Plough/Merck & Co., and Bristol-Myers Squibb.

Author information

Authors and Affiliations

  1. Toronto Western Research Institute; Psoriatic Arthritis Program, University Health Network, University of Toronto, 399 Bathurst Street, 1E-410B, Toronto, Ontario, M5T 2S8, Canada

    Dafna D. Gladman & Vinod Chandran

Authors
  1. Dafna D. Gladman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vinod Chandran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dafna D. Gladman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gladman, D.D., Chandran, V. Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future?. Curr Rheumatol Rep 13, 346–352 (2011). https://doi.org/10.1007/s11926-011-0182-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0182-x

Keywords

Search

Navigation